Dihydropyrrolopyridine inhibitors of ROR-gamma
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR . Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
1. A compound of the Formula:
or a pharmaceutically acceptable salt thereof, wherein
R 2 is (C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, benzyl, (C 1 -C 3 )alkoxy(C 1 -C 3 )alkyl, tetrahydropyranyl, or —CH 2 -tetrahydropyranyl;
R 3 and R 4 are each independently hydrogen or methyl;
Cy 1 is phenyl or pyridyl, each substituted with (C 1 -C 3 )alkylsulfonyl; and
Cy 2 is hydrogen, halo(C 1 -C 3 )alkyl, cyclohexyl, or tetrahydropyranyl, wherein the cyclohexyl and tetrahydropyranyl are each optionally substituted with one or more groups selected from halo(C 1 -C 3 )alkyl and C 1 -C 3 (alkoxy).
2. The compound of claim 1 , wherein the compound is of the Formula:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is of the Formula:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3 , wherein the compound is of the Formula:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 , wherein Cy 2 is cyclohexyl or tetrahydropyranyl, each of which are optionally substituted with one or more groups selected from halo (C 1 -C 3 )alkyl and C 1 -C 3 (alkoxy).
6. The compound of claim 5 , wherein the compound is of the Formula:
or a pharmaceutically acceptable salt thereof, wherein
X is CH or N;
Y 1 is O and Y 2 is CH 2 , Y 1 is CH 2 and Y 2 is O, or Y 1 and Y 2 are each CH 2 ;
R 9 is halo(C 1 -C 3 )alkyl; and
R 10 is (C 1 -C 3 )alkylsulfonyl.
7. The compound of claim 6 , wherein the compound is of the Formula:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 7 , wherein the compound is of the Formula:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 8 , wherein R 2 is methyl, ethyl, benzyl, or isopropyl.
10. The compound of claim 9 , wherein R 2 is ethyl or isopropyl.
11. The compound of claim 10 , wherein R 9 is CF 3 ; and R 10 is SO 2 Et or SO 2 Me.
12. The compound of claim 1 , wherein the compound is selected from
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. A method of treating psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, ankylosing spondylitis, and asthma in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.